JJJason Jenkins

Jason Jenkins

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jason Jenkins has a total of 48 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Use of artificial intelligence-assisted measurement of aortic diameter in clinical decision making about abdominal aortic aneurysm repair

    by Chinmay Sharma, Mike Wu, Aditya Enjeti, Shivshankar Thanigaimani, Jason Jenkins, Frank Quigley, Jonathan Golledge

    Objectives Decisions to perform abdominal aortic aneurysm (AAA) repair are dependent on aneurysm size, but variation in size measurement leads to inconsistency in management. AI-assisted systems have potential to improve repeatability of measuring aortic dimensions. This study compared the repeatability and agreement in clinical decision-making between using artificial intelligence (AI)-automated and traditional semi-automated methods for measuring abdominal aortic aneurysm (AAA) size. Materials and methods Computed tomography angiogram scans from 142 patients who had scans at baseline (n = 142), 1 year (n = 100), 2 years (n = 56) and 3 years (n = 4) were analysed using semi-automated and AI-assisted automated systems. Three observers measured maximal AAA diameter and volume twice with each method. Intra- and inter-observer repeatability were assessed using reproducibility coefficients (RC). Measurements were used to decide if AAA repair was required according to clinical guidelines, and agreement was evaluated using Kappa coefficients (K). The ability of AI-assisted measurements to predict actual requirement for AAA repair was assessed using Cox proportional hazard analysis. Results AI-assisted measurements had perfect intra- and inter-observer repeatability (RC = 0) which were significantly superior to traditional measurements (RC for diameter: 1.9–5.6 mm; volume: 7.8–22.6 cm³, p < 0.001). Agreement about AAA repair was superior using AI-assisted (K = 1) than traditional (K = 0.55–0.70) measurements. Baseline AI-assisted measurements predicted actual requirement for AAA repair (Hazard ratio, HR, per mm diameter increase 1.12, 95% confidence intervals, CI, 1.03–1.22, HR per cm³ volume increase 1.02, 95% CI 1.01–1.02, p < 0.001). Conclusion The findings suggest AI-assisted measurement of AAA size would enhance the consistency of decisions about AAA repair.


  • Open Access

    Enhancing compliance and extracellular matrix properties of tissue-engineered vascular grafts through pulsatile bioreactor culture

    by Angus Weekes, Jordan W. Davern, Nigel Pinto, Jason Jenkins, Zhiyong Li, Christoph Meinert, Travis J. Klein


  • Open Access

    Harnessing the Regenerative Potential of Fetal Mesenchymal Stem Cells and Endothelial Colony‐Forming Cells in the Biofabrication of Tissue‐Engineered Vascular Grafts (TEVGs)

    by Angus Weekes, Joanna M. Wasielewska, Nigel Pinto, Jason Jenkins, Jatin Patel, Zhiyong Li, Travis J. Klein, Christoph Meinert

    Tissue engineering is a promising approach for the production of small‐diameter vascular grafts; however, there are limited data directly comparing the suitability of applicable cell types for vessel biofabrication. Here, we investigated the potential of adult smooth muscle cells (SMCs), placental mesenchymal stem cells (MSCs), placental endothelial colony‐forming cells (ECFCs), and a combination of MSCs and ECFCs on highly porous biocompatible poly(ɛ‐caprolactone) (PCL) scaffolds produced via melt electrowriting (MEW) for the biofabrication of tissue‐engineered vascular grafts (TEVGs). Cellular attachment, proliferation, and deposition of essential extracellular matrix (ECM) components were analysed in vitro over four weeks. TEVGs cultured with MSCs accumulated the highest levels of collagenous components within a dense ECM, while SMCs and the coculture were more sparsely populated, ascertained via histological and immunofluorescence imaging, and biochemical assessment. Scanning electron microscopy (SEM) enabled visualisation of morphological differences in cell attachment and growth, with MSCs and SMCs infiltrating and covering scaffolds completely within the 28‐day culture period. Coverage and matrix deposition by ECFCs was limited. However, ECFCs lined the ECM formed by MSCs in coculture, visualised via immunostaining. Thus, of cells investigated, placental MSCs were identified as the preferred cell source for the fabrication of tissue‐engineered constructs, exhibiting extensive population of porous polymer scaffolds and production of ECM components; with the inclusion of ECFCs for luminal endothelialisation, an encouraging outcome warranting further consideration in future studies. In combination, these findings represent a substantial step toward the development of the next generation of small‐diameter vascular grafts in the management of cardiovascular disease.


  • Open Access

    Highly compliant biomimetic scaffolds for small diameter tissue-engineered vascular grafts (TEVGs) produced via melt electrowriting (MEW)

    by Angus Weekes, Gabrielle Wehr, Nigel Pinto, Jason Jenkins, Zhiyong Li, Christoph Meinert, Travis J Klein

    Biofabrication approaches toward the development of tissue-engineered vascular grafts (TEVGs) have been widely investigated. However, successful translation has been limited to large diameter applications, with small diameter grafts frequently failing due to poor mechanical performance, in particular mismatched radial compliance. Herein, melt electrowriting (MEW) of poly(ϵ-caprolactone) has enabled the manufacture of highly porous, biocompatible microfibre scaffolds with physiological anisotropic mechanical properties, as substrates for the biofabrication of small diameter TEVGs. Highly reproducible scaffolds with internal diameter of 4.0 mm were designed with 500 and 250 µm pore sizes, demonstrating minimal deviation of less than 4% from the intended architecture, with consistent fibre diameter of 15 ± 2 µm across groups. Scaffolds were designed with straight or sinusoidal circumferential microfibre architecture respectively, to investigate the influence of biomimetic fibre straightening on radial compliance. The results demonstrate that scaffolds with wave-like circumferential microfibre laydown patterns mimicking the architectural arrangement of collagen fibres in arteries, exhibit physiological compliance (12.9 ± 0.6% per 100 mmHg), while equivalent control geometries with straight fibres exhibit significantly reduced compliance (5.5 ± 0.1% per 100 mmHg). Further mechanical characterisation revealed the sinusoidal scaffolds designed with 250 µm pores exhibited physiologically relevant burst pressures of 1078 ± 236 mmHg, compared to 631 ± 105 mmHg for corresponding 500 µm controls. Similar trends were observed for strength and failure, indicating enhanced mechanical performance of scaffolds with reduced pore spacing. Preliminary in vitro culture of human mesenchymal stem cells validated the MEW scaffolds as suitable substrates for cellular growth and proliferation, with high cell viability (>90%) and coverage (>85%), with subsequent seeding of vascular endothelial cells indicating successful attachment and preliminary endothelialisation of tissue-cultured constructs. These findings support further investigation into long-term tissue culture methodologies for enhanced production of vascular extracellular matrix components, toward the development of the next generation of small diameter TEVGs.


  • Open Access

    Association of Oral Anticoagulation Prescription with Clinical Events in Patients with an Asymptomatic Unrepaired Abdominal Aortic Aneurysm

    by Jonathan Golledge, Jason Jenkins, Michael Bourke, Bernard Bourke, Tejas P. Singh

    Background: Most abdominal aortic aneurysms (AAA) have large volumes of intraluminal thrombus which has been implicated in promoting the risk of major adverse events. The aim of this study was to examine the association of therapeutic anticoagulation with AAA-related events and major adverse cardiovascular events (MACE) in patients with an unrepaired AAA. Methods: Patients with an asymptomatic unrepaired AAA were recruited from four sites in Australia. The primary outcome was the combined incidence of AAA repair or AAA rupture-related mortality (AAA-related events). The main secondary outcome was MACE (the combined incidence of myocardial infarction, stroke, or cardiovascular death). The associations of anticoagulation with these outcomes were assessed using Cox proportional hazard analyses (reporting hazard ratio, HR, and 95% confidence intervals, CI) to adjust for other risk factors. Results: A total of 1161 patients were followed for a mean (standard deviation) of 4.9 (4.0) years. Of them, 536 (46.2%) patients had a least one AAA-related event and 319 (27.5%) at least one MACE. In the sample, 98 (8.4%) patients were receiving long-term therapeutic anticoagulation using warfarin (84), apixaban (7), rivaroxaban (6), or dabigatran (1). Prescription of an anticoagulant was associated with a reduced risk of an AAA-related event (adjusted HR 0.61; 95% CI 0.42, 0.90, p = 0.013), but not MACE (HR 1.16; 95% CI 0.78, 1.72, p = 0.476). Conclusions: These findings suggest that AAA-related events but not MACE may be reduced in patients prescribed an anticoagulant medication. Due to the inherent biases of observational studies, a randomized controlled trial is needed to assess whether anticoagulation reduces the risk of AAA-related events.


  • Biofabrication of small diameter tissue-engineered vascular grafts

    by Angus Weekes, Nicole Bartnikowski, Nigel Pinto, Jason Jenkins, Christoph Meinert, Travis J. Klein


  • Open Access

    Inositol in the MAnaGemENt of abdominal aortic aneurysm (IMAGEN): study protocol for a randomised controlled trial

    by Sophie E. Rowbotham, Jenna L. Pinchbeck, Georgina Anderson, Bernie Bourke, Michael Bourke, T. Christian Gasser, Rene Jaeggi, Jason S. Jenkins, Corey S. Moran, Susan K. Morton, et al.

    An abdominal aortic aneurysm (AAA) is a focal dilation of the abdominal aorta and is associated with a risk of fatal rupture. Experimental studies suggest that myo-inositol may exert beneficial effects on AAAs through favourable changes to biological pathways implicated in AAA pathology. The aim of the Inositol in the MAnaGemENt of abdominal aortic aneurysm (IMAGEN) trial is to assess if myo-inositol will reduce AAA growth. IMAGEN is a multi-centre, prospective, parallel-group, randomised, double-blind, placebo-controlled trial. A total of 164 participants with an AAA measuring ≥ 30 mm will be randomised to either 2 g of myo-inositol or identical placebo twice daily for 12 months. The primary outcome measure will be AAA growth estimated by increase in total infrarenal aortic volume measured on computed tomographic scans. Secondary outcome measures will include AAA diameter assessed by computed tomography and ultrasound, AAA peak wall stress and peak wall rupture index, serum lipids, circulating AAA biomarkers, circulating RNAs and health-related quality of life. All analysis will be based on the intention-to-treat principle at the time of randomisation. All patients who meet the eligibility criteria, provide written informed consent and are enrolled in the study will be included in the primary analysis, regardless of adherence to dietary allocation. Currently, there is no known medical therapy to limit AAA progression. The IMAGEN trial will be the first randomised trial, to our knowledge, to assess the value of myo-inositol in limiting AAA growth. Australian New Zealand Clinical Trials Registry, ACTRN12615001209583 . Registered on 6 November 2015.


  • Top Cited Papers
    Open Access

    Fenofibrate in the management of AbdoMinal aortic anEurysm (FAME): study protocol for a randomised controlled trial

    by Sophie E. Rowbotham, Doug Cavaye, Rene Jaeggi, Jason S. Jenkins, Corey S. Moran, Joseph V. Moxon, Jenna L. Pinchbeck, Frank Quigley, Christopher M. Reid, Jonathan Golledge

    Abdominal aortic aneurysm (AAA) is a slowly progressive destructive process of the main abdominal artery. Experimental studies indicate that fibrates exert beneficial effects on AAAs by mechanisms involving both serum lipid modification and favourable changes to the AAA wall. Fenofibrate in the management of AbdoMinal aortic anEurysm (FAME) is a multicentre, randomised, double-blind, placebo-controlled clinical trial to assess the effect of orally administered therapy with fenofibrate on key pathological markers of AAA in patients undergoing open AAA repair. A total of 42 participants scheduled for an elective open AAA repair will be randomly assigned to either 145 mg of fenofibrate per day or identical placebo for a minimum period of 2 weeks prior to surgery. Primary outcome measures will be macrophage number and osteopontin (OPN) concentration within the AAA wall as well as serum concentrations of OPN. Secondary outcome measures will include levels of matrix metalloproteinases and proinflammatory cytokines within the AAA wall, periaortic fat and intramural thrombus and circulating concentrations of AAA biomarkers. At present, there is no recognised medical therapy to limit AAA progression. The FAME trial aims to assess the ability of fenofibrate to alter tissue markers of AAA pathology. Australian New Zealand Clinical Trials Registry, ACTRN12612001226897 . Registered on 20 November 2012.


  • Open Access

    Efficacy of brief behavioral counselling by allied health professionals to promote physical activity in people with peripheral arterial disease (BIPP): study protocol for a multi-center randomized controlled trial

    by Nicola W. Burton, Zanfina Ademi, Stuart Best, Maria A. Fiatarone Singh, Jason S. Jenkins, Kenny D. Lawson, Anthony S. Leicht, Yorgi Mavros, Yian Noble, Paul Norman, et al.

    Physical activity is recommended for people with peripheral arterial disease (PAD), and can improve walking capacity and quality of life; and reduce pain, requirement for surgery and cardiovascular events. This trial will assess the efficacy of a brief behavioral counselling intervention delivered by allied health professionals to improve physical activity in people with PAD. This is a multi-center randomised controlled trial in four cities across Australia. Participants (N = 200) will be recruited from specialist vascular clinics, general practitioners and research databases and randomised to either the control or intervention group. Both groups will receive usual medical care, a written PAD management information sheet including advice to walk, and four individualised contacts from a protocol-trained allied health professional over 3 months (weeks 1, 2, 6, 12). The control group will receive four 15-min telephone calls with general discussion about PAD symptoms and health and wellbeing. The intervention group will receive behavioral counselling via two 1-h face-to-face sessions and two 15-min telephone calls. The counselling is based on the 5A framework and will promote interval walking for 3 × 40 min/week. Assessments will be conducted at baseline, and 4, 12 and 24 months by staff blinded to participant allocation. Objectively assessed outcomes include physical activity (primary), sedentary behavior, lower limb body function, walking capacity, cardiorespiratory fitness, event-based claudication index, vascular interventions, clinical events, cardiovascular function, circulating markers, and anthropometric measures. Self-reported outcomes include physical activity and sedentary behavior, walking ability, pain severity, and health-related quality of life. Data will be analysed using an intention-to-treat approach. An economic evaluation will assess whether embedding the intervention into routine care would likely be value for money. A cost-effectiveness analysis will estimate change in cost per change in activity indicators due to the intervention, and a cost-utility analysis will assess change in cost per quality-adjusted life year. A full uncertainty analysis will be undertaken, including a value of information analysis, to evaluate the economic case for further research. This trial will evaluate the efficacy and cost-effectiveness of a brief behavioral counselling intervention for a common cardiovascular disease with significant burden. ACTRN 12614000592640 Australian New Zealand Clinical Trials Registry. Registration Date 4 June 2014.


  • Extra-Anatomic Axillo–Mesenteric Reconstruction for Chronic Mesenteric Ischemia

    by Lisa L. Wang, Andrew M.T.L. Choong, Alexandra Kovalic, Jason Jenkins, Allan Kruger